Novartis AG stock (CH0012005267): spin-off completed, Q1 figures highlight new focus

Novartis AG has sharpened its focus on innovative medicines after completing the Sandoz spin-off and publishing Q1 2026 results. We explain the latest numbers, strategic priorities and what the streamlined pharma group means for globally oriented US investors.

Novartis AG has started 2026 as a more focused pharmaceuticals group after spinning off its generics unit Sandoz in late 2023 and reporting first-quarter 2026 results that underline its shift toward innovative medicines and higher-margin therapies, according to a company earnings release published on 04/23/2026 and subsequent coverage from Reuters as of 04/23/2026.

As of: 23.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Novartis
• Sector/industry: Pharmaceuticals, biotechnology, healthcare
• Headquarters/country: Basel, Switzerland
• Core markets: Global prescription drug markets in the US, Europe and key emerging regions
• Key revenue drivers: Innovative prescription medicines in oncology, cardiovascular and immunology, plus ophthalmology and neuroscience
• Home exchange/listing venue: SIX Swiss Exchange (NOVN), secondary listing on NYSE (NVS)
• Trading currency: Swiss franc on SIX, US dollar on NYSE

Novartis AG: core business model

Novartis AG is one of the world’s largest research-driven pharmaceutical groups, focusing on patented prescription medicines for serious and chronic diseases. After the separation of its generics business Sandoz through a spin-off completed in October 2023, Novartis now concentrates on innovative medicines and oncology, where intellectual property and clinical data create long product cycles and high entry barriers, as outlined in the company’s 2023 annual report published in January 2024 and summarized by Novartis investor materials as of 01/31/2024.

The group organizes its business primarily around therapeutic areas such as oncology, cardiovascular, renal and metabolic diseases, immunology, neuroscience and ophthalmology. Within these areas, Novartis develops and commercializes small molecules and biologic drugs, including complex cell and gene therapies. The business model relies on substantial upfront research and development spending, followed by multi-year commercial rollouts once regulators approve new medicines for broad indications in major markets like the United States, the European Union and Japan.

Revenue generation for Novartis is supported by a combination of newly launched growth products and established blockbusters that still benefit from patent protection. Over time, the company must replace maturing products with new therapies in earlier stages of the pipeline. This innovation cycle is at the core of the model: successful late-stage clinical trials, regulatory approvals and reimbursement decisions by payers are critical milestones that determine whether individual projects translate into sustainable revenue streams, as highlighted in the firm’s pipeline updates and capital markets presentations shared with investors in 2024 and 2025.

Geographically, Novartis generates a large share of its sales in the United States, which is the world’s largest pharmaceuticals market by value and a key profit contributor due to comparatively higher pricing levels. Europe and other developed markets such as Japan and Canada represent additional pillars, while emerging markets in Asia, Latin America and the Middle East provide incremental volume growth. This broad geographic footprint helps diversify reimbursement and regulatory risk, but also exposes the company to currency fluctuations and differing national healthcare policies.

Main revenue and product drivers for Novartis AG

The revenue base of Novartis is concentrated in a series of blockbuster and near-blockbuster therapies, many of which are prescribed in specialized settings by oncologists, cardiologists and neurologists. Among its key franchises are oncology medicines for blood cancers and solid tumors, cardiovascular drugs targeting heart failure or lipid disorders, and immunology products for autoimmune conditions. The company’s Q1 2026 report emphasized the contribution of these innovative brands, which supported both reported sales growth and margin expansion in the quarter, according to the earnings release dated 04/23/2026 and recapped by Novartis Investors as of 04/23/2026.

In oncology, therapies for hematological malignancies and targeted treatments for specific genetic mutations are central growth drivers. These medicines typically command high prices due to their specialized indications and the significant clinical benefit they can deliver in terms of survival or disease control. However, the oncology portfolio is also exposed to intense competition from other global pharmaceutical and biotech companies developing rival drugs, as well as from biosimilars that may erode sales once patents expire. The need to defend or extend product lifecycles through new indications and combination therapies is therefore a constant strategic priority.

Cardiovascular and metabolic products represent another major pillar, with Novartis marketing medicines for conditions such as heart failure and hypercholesterolemia. These therapies benefit from large patient populations and long treatment durations, but they must navigate evolving treatment guidelines and reimbursement frameworks. In this space, Novartis competes with other large pharmaceutical companies and, increasingly, with novel drug classes such as GLP-1-based therapies for obesity and diabetes. The company’s strategy has centered on demonstrating strong outcomes data and real-world evidence to support the value proposition of its cardiovascular drugs to payers and clinicians.

Beyond these established areas, Novartis has invested in advanced therapy platforms, including cell and gene therapies that aim to treat diseases at their root genetic cause. While these treatments can command premium prices and address high unmet medical needs, they also come with complex manufacturing requirements, stringent regulatory scrutiny and reimbursement challenges given their high upfront costs. The Q1 2026 figures and accompanying commentary indicated that Novartis continues to refine its approach to these advanced modalities, focusing on indications where the clinical benefit and economic case are most compelling for healthcare systems in core markets.

Why Novartis AG matters for US investors

Even though Novartis is headquartered in Switzerland, the group maintains a strong presence in the United States through its NYSE listing under the ticker NVS, its extensive clinical trial network and its significant commercial footprint in key therapeutic areas. For US-based investors, the stock offers exposure to global pharmaceutical innovation and to revenue streams that are partly denominated in US dollars but also diversified across other currencies. This can create both opportunities and risks, particularly in periods of pronounced exchange rate volatility.

The US market is a crucial driver of profitability for Novartis because of its size and its role as a global launch market for new drugs. Successful commercialization in the United States often sets the tone for how a therapy will be adopted elsewhere, and price levels established during US negotiations with payers tend to influence international reference pricing frameworks. At the same time, the US policy landscape is becoming more demanding, with initiatives such as Medicare drug price negotiations and greater scrutiny of specialty drug spending potentially affecting long-term revenue trajectories in areas like oncology and cardiology, as highlighted in sector commentary by major financial media outlets during 2024 and early 2025.

From a portfolio construction perspective, Novartis shares may play a role for US investors seeking sector diversification beyond domestic pharmaceutical majors. The company’s European base, combined with its global sales mix, can offer a different regulatory and reimbursement profile compared with pure US peers. In addition, the stock’s historical emphasis on dividends and buybacks, as communicated in prior capital allocation updates, means that total return is not solely a function of top-line growth but also of shareholder distributions and capital structure management. However, these policies remain subject to board decisions, underlying cash flow generation and strategic priorities such as bolt-on acquisitions.

Conclusion

Novartis AG is navigating 2026 as a streamlined innovative medicines group whose fortunes hinge on the success of its late-stage pipeline, the sustained performance of its key oncology and cardiovascular franchises and an evolving policy environment in major markets such as the United States and Europe. The completion of the Sandoz spin-off and the latest quarterly results underline management’s focus on higher-margin branded drugs, but this strategy also increases dependence on a smaller set of high-value assets and on continued regulatory approvals. For globally oriented US investors, Novartis offers exposure to a diversified pharmaceutical portfolio with meaningful US market presence and a European corporate governance framework, balanced by risks around patent cliffs, pricing pressures and currency fluctuations.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.